63894-54-2

Basic information

• Product Name: (5,6-DIMETHYL-THIENO[2,3-D]PYRIMIDIN-4-YL)-HYDRAZINE
• Synonyms: 4-hydrazino-5,6-dimethylthieno[2,3-d]pyrimidine(SALTDATA: FREE);4-Hydrazinyl-5,6-diMethylthieno[2,3-d]pyriMidine
• CAS NO: 63894-54-2
• Molecular Formula: C₈H₁₀N₄S
• Molecular Weight: 194.26
• Mol File: 63894-54-2.mol

Chemical Properties

• Boiling Point: 425.4°C at 760 mmHg
• Flash Point: 211°C
• Appearance: /
• Density: 1.401g/cm³
• Vapor Pressure: 1.93E-07mmHg at 25°C
• Refractive Index: 1.755
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5,6-DIMETHYL-THIENO[2,3-D]PYRIMIDIN-4-YL)-HYDRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (5,6-DIMETHYL-THIENO[2,3-D]PYRIMIDIN-4-YL)-HYDRAZINE(63894-54-2)
• EPA Substance Registry System: (5,6-DIMETHYL-THIENO[2,3-D]PYRIMIDIN-4-YL)-HYDRAZINE(63894-54-2)

Safety Data

• Statements: 20/21/22
• Safety Statements: 36/37/39
• Hazardous Substances Data: 63894-54-2(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C8H10N4S/c1-4-5(2)13-8-6(4)7(12-9)10-3-11-8/h3H,9H2,1-2H3,(H,10,11,12)

Upstream product

• 4815-24-1 2-amino-4,5-dimethyl-3-thiophenecarboxylic acid ethyl ester 
• 18593-44-7 5,6-dimethylthieno<2,3-d>pyrimidin-4(3H)-one 
• 108831-68-1 4-chloro-5,6-dimethyl-thieno[2,3-d]pyrimidine 

Relevant articles and documents

Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C2and C6positions

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cell. In AML, a mutation in FLT3 is commonly occurs and is associated with poor prognosis. We have previously reported that thieno[2,3-d]pyrimidine derivative compound 1 exhibited better antiproliferative activity against MV4-11 cells which harbor mutant FLT3 than AC220, which is a well-known FLT3 inhibitor, and has good microsomal stability. However, compound 1 had poor solubility. We then carried out further structural modification at the C2and the C6positions of thieno[2,3-d]pyrimidine scaffold. Compound 13b, which possesses a thiazole moiety at the C2position, exhibited better antiproliferative activity than compound 1 and showed increased solubility and moderate microsomal stability. These results indicate that compound 13b could be a promising potential FLT inhibitor for AML chemotherapy.

Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication

A structure-based virtual screening technique was applied to the study of the HCV NS3 helicase, with the aim to find novel inhibitors of the HCV replication. A library of ～450000 commercially available compounds was analysed in silico and 21 structures were selected for biological evaluation in the HCV replicon assay. One hit characterized by a substituted thieno-pyrimidine scaffold was found to inhibit the viral replication with an EC50value in the sub-micromolar range and a good selectivity index. Different series of novel thieno-pyrimidine derivatives were designed and synthesised; several new structures showed antiviral activity in the low or sub-micromolar range.